La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Compugen Dividendo

Dividendo criteri di controllo 0/6

Compugen non ha registrato alcun pagamento di dividendi.

Informazioni chiave

n/a

Rendimento del dividendo

n/a

Rapporto di remunerazione

Rendimento medio del settore	1.9%
Prossima data di pagamento dei dividendi	n/a
Data di stacco del dividendo	n/a
Dividendo per azione	n/a
Utile per azione	-US$0.11
Previsione del rendimento del dividendo	n/a

Aggiornamenti recenti sui dividendi

Nessun aggiornamento

Recent updates

Investors Aren't Buying Compugen Ltd.'s (NASDAQ:CGEN) Revenues

Aug 22

Analysts Have Been Trimming Their Compugen Ltd. (NASDAQ:CGEN) Price Target After Its Latest Report

May 22

Why Investors Shouldn't Be Surprised By Compugen Ltd.'s (NASDAQ:CGEN) 25% Share Price Plunge

May 01

Is Compugen Ltd. (NASDAQ:CGEN) Trading At A 36% Discount?

Apr 05

Compugen Ltd.'s (NASDAQ:CGEN) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Mar 08

Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation

Mar 04

Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Sep 21

Compugen appoints Alberto Sessa as CFO

Sep 12

Compugen gets Japanese patent for COM701, anti-PVRIG antibodies

Aug 24

Compugen Q2 2022 Earnings Preview

Aug 03

Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Jun 23

Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Mar 02

Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation

Nov 04

Shareholders Will Probably Not Have Any Issues With Compugen Ltd.'s (NASDAQ:CGEN) CEO Compensation

Aug 27

Companies Like Compugen (NASDAQ:CGEN) Can Afford To Invest In Growth

Jun 28

Compugen gains on takeover speculation after iTeos Therapeutics deal

Jun 14

Compugen reports updated COM701 data from Phase 1 study at ASCO21

Jun 08

Compugen's COM902 demonstrates potential benefit in cancer

Apr 27

Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation

Mar 15

Are Institutions Heavily Invested In Compugen Ltd.'s (NASDAQ:CGEN) Shares?

Feb 08

A Look At The Fair Value Of Compugen Ltd. (NASDAQ:CGEN)

Jan 04

Compugen earns $2M milestone under antibody development deal with AstraZeneca

Dec 23

Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation

Nov 30

Compugen Ltd. 2020 Q3 - Results - Earnings Call Presentation

Nov 08

Compugen: Speculative Play For Immuno-Oncology Exposure

Nov 07

Compugen Q3 Earnings Preview

Nov 04

Stabilità e crescita dei pagamenti

Recupero dei dati sui dividendi

Dividendo stabile: Dati insufficienti per determinare se i dividendi per azione di CGEN siano rimasti stabili in passato.

Dividendo in crescita: Dati insufficienti per determinare se i pagamenti dei dividendi di CGEN siano aumentati.

Rendimento dei dividendi rispetto al mercato

Compugen Rendimento dei dividendi rispetto al mercato

Come si colloca il rendimento da dividendo di CGEN rispetto al mercato?
Segmento	Rendimento dei dividendi
Azienda (CGEN)	n/a
Fondo del 25% del mercato (US)	1.4%
Top 25% del mercato (US)	4.3%
Media del settore (Biotechs)	1.9%
Analista previsionale (CGEN) (fino a 3 anni)	n/a

Dividendo notevole: Impossibile valutare il rendimento dei dividendi di CGEN rispetto al 25% inferiore dei pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Dividendo elevato: Impossibile valutare il rendimento dei dividendi di CGEN rispetto al 25% dei maggiori pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Distribuzione degli utili agli azionisti

Copertura degli utili: Dati insufficienti per calcolare il payout ratio di CGEN per determinare se i suoi pagamenti di dividendi sono coperti dagli utili.

Pagamenti in contanti agli azionisti

Copertura del flusso di cassa: Impossibile calcolare la sostenibilità dei dividendi poiché CGEN non ha segnalato alcun pagamento.

Compugen Dividendo

Dividendo criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sui dividendi

Recent updates

Investors Aren't Buying Compugen Ltd.'s (NASDAQ:CGEN) Revenues

New minor risk - Profitability

New major risk - Revenue and earnings growth

Forecast to breakeven in 2025

Compugen Ltd., Annual General Meeting, Sep 12, 2024

Compugen Ltd. Announces FDA Clearance of IND for Com503 for the Treatment of Solid Tumors

Compugen Ltd. to Report Q2, 2024 Results on Aug 06, 2024

Analysts Have Been Trimming Their Compugen Ltd. (NASDAQ:CGEN) Price Target After Its Latest Report

Compugen Ltd. Announces CFO Changes, Effective August 15, 2024

Compugen Ltd. to Report Q1, 2024 Results on May 20, 2024

Why Investors Shouldn't Be Surprised By Compugen Ltd.'s (NASDAQ:CGEN) 25% Share Price Plunge

Is Compugen Ltd. (NASDAQ:CGEN) Trading At A 36% Discount?

New minor risk - Shareholder dilution

Consensus revenue estimates increase by 41%, EPS downgraded

Now 23% undervalued

New major risk - Revenue and earnings growth

Compugen Ltd.'s (NASDAQ:CGEN) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Compugen Ltd. to Report Q4, 2023 Results on Mar 05, 2024

Compugen (NASDAQ:CGEN) Is In A Good Position To Deliver On Growth Plans

Compugen Ltd. Announces Executive Changes

New major risk - Revenue and earnings growth

Consensus revenue estimates fall by 45%

Compugen Announces Receipt of Nasdaq Minimum Bid Price Notification

Compugen Ltd. Announces to Present New Data At Sitc 2023 Suggesting Leading Edge of Anti-Il18 Binding Protein Antibody, Com503, in Treating Cancer

Compugen Ltd. to Report Q3, 2023 Results on Nov 07, 2023

Will Compugen (NASDAQ:CGEN) Spend Its Cash Wisely?

Insufficient new directors

New major risk - Revenue and earnings growth

Consensus EPS estimates upgraded to US$0.31 loss

Compugen Ltd., Annual General Meeting, Sep 20, 2023

Compugen Ltd. to Report Q2, 2023 Results on Aug 07, 2023

Price target decreased by 7.0% to US$5.50

Compugen Ltd. Doses First Patient in Triple Immunotherapy Combination COM701, COM902 and Pembrolizumab Platinum Resistant Ovarian Cancer Proof-Of-Concept Study

Is Compugen (NASDAQ:CGEN) In A Good Position To Invest In Growth?

Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement

Price target increased by 15% to US$6.80

Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation

Compugen Ltd. to Report Q4, 2022 Results on Feb 27, 2023

Compugen Ltd.'s COM701 (anti-PVRIG) in Dual and Triple Combination Demonstrates Preliminary Durable Anti-Tumor Activity and Immune Activation in Patients with Platinum Resistant Ovarian Cancer

Price target decreased to US$6.29

Compugen Demonstrates Preliminary Anti-Tumor Activity and Potent Immune Activation in Metastatic MSS-CRC Patients

Compugen Announces Receipt of Nasdaq Delisting Notice

Compugen Ltd. to Report Q3, 2022 Results on Nov 14, 2022

Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Compugen Ltd. Announces Appointment of Alberto Sessa as Chief Financial Officer

Compugen appoints Alberto Sessa as CFO

Compugen gets Japanese patent for COM701, anti-PVRIG antibodies

Compugen Ltd. Announces Resignation of Ari Krashin as Chief Operating Officer in August 2022

Compugen Q2 2022 Earnings Preview

Compugen Ltd. to Report Q2, 2022 Results on Aug 04, 2022

Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Compugen Announces CFO Departure

Compugen Ltd. to Report Q1, 2022 Results on May 16, 2022

Price target decreased to US$14.00

Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Compugen Ltd. Announces Board Changes

Compugen Ltd. to Report Q4, 2021 Results on Feb 24, 2022

Price target decreased to US$18.57

Compugen Expands COM701 Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use with anti-PD-1 and anti-TIGIT Antibodies

Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation

Shareholders Will Probably Not Have Any Issues With Compugen Ltd.'s (NASDAQ:CGEN) CEO Compensation

Compugen Announces Bispecific Antibody Derived from COM902 to Enter Clinical Development

High number of new directors

Compugen Doses First Patient in Phase 1/2 Triple Combination Cohort Expansion of COM701 with Opdivo® and Bristol Myers Squibb's Anti-TIGIT Antibody, BMS-986207

Compugen Doses First Patient in Phase 1 Combination Study of COM902 and COM701 in Patients with Advanced Malignancies

Senior VP & Chief Medical Officer notifies of intention to sell stock

Compugen Doses First Patient in COM701/Opdivo® (nivolumab) Phase 1b Cohort Expansion Study

Compugen Ltd. Presents Research Supporting PVRIG as a Novel and Differentiated Checkpoint in the DNAM-1 Axis

Companies Like Compugen (NASDAQ:CGEN) Can Afford To Invest In Growth

Compugen gains on takeover speculation after iTeos Therapeutics deal

Compugen Ltd. Updates Data from Phase 1 Study of COM701

Compugen reports updated COM701 data from Phase 1 study at ASCO21

Compugen Publishes Preclinical Data Demonstrating Therapeutic Potential of COM902 in Cancer Immunology, Immunotherapy

Compugen's COM902 demonstrates potential benefit in cancer

Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation